Immunovaccine, Leidos to collaborate on Zika virus vaccine
“Our virtual pharma approach ensures that we are not beholden to a particular technology or laboratory,” Leidos Deputy Group President Jerry Hogge said. “We are able to seek the best solutions to suit the project at hand. This includes our partnership with Immunovaccine, which leverages the best capabilities of both companies.”
Leidos will lead efforts to discover and develop antigens and determine which ones are the best candidates to prevent Zika infection using its Virtual Pharmaceutical Development Program. Immunovaccine will build on Leidos’ work to formulate new antigens in its DepoVax delivery system, which has shown successful results in combating Ebola virus, anthrax and respirator syncytial virus (RSV).
“While we remain focused on immuno-oncology, collaborations with partners like Leidos allow us to expand the use and potential value of our platform technology in other applications and markets,” Immunovaccine's acting CEO Frederic Ors said. “This first collaboration on a Zika virus vaccine builds on our previous success in developing candidate vaccines that show promise in providing one-dose, fast-acting protection.”